JAMES BLACKWOOD: Open Payments
NPI 1124548011 · SCOTTSBORO, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$878 in 38 payments from 15 companies in 2025. Trend: 2023 $1,446 · 2024 $632 · 2025 $878
Food & beverage: $878
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $260 |
| Corcept Therapeutics | 7 | $171 |
| ABBVIE INC. | 5 | $116 |
| Dexcom, Inc. | 2 | $46 |
| Vanda Pharmaceuticals Inc. | 2 | $43 |
| AstraZeneca Pharmaceuticals LP | 2 | $39 |
| Astellas Pharma US Inc | 1 | $30 |
| Lilly USA, LLC | 1 | $26 |
| Pharmacosmos Therapeutics Inc. | 1 | $26 |
| Lundbeck LLC | 1 | $24 |
Products named: CAPLYTA, Korlym, VRAYLAR, Dexcom G6 Transmitter, FANAPT, Veozah, JARDIANCE, MONOFERRIC.
Industry payments across AL — which companies pay providers there.
